Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise

To test the hypothesis that delayed onset muscular soreness (DOMS) following intense eccentric muscle contraction could be due to increased production of prostaglandin E2 (PGE2), ten healthy male subjects were studied. Using a double-blind randomized crossover design, each subject performed two isok...

Full description

Saved in:
Bibliographic Details
Main Authors: J-L. Croisier, G. Camus, T. Monfils, G. Deby-Dupon, M. Fafchamps, I. Venneman, J-M. Crielaard, A. Juchmès-Ferir, C. Lhermerout, M. Lamy, C. Deby
Format: Article
Language:English
Published: Wiley 1996-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/S0962935196000336
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849686109048537088
author J-L. Croisier
G. Camus
T. Monfils
G. Deby-Dupon
M. Fafchamps
I. Venneman
J-M. Crielaard
A. Juchmès-Ferir
C. Lhermerout
M. Lamy
C. Deby
author_facet J-L. Croisier
G. Camus
T. Monfils
G. Deby-Dupon
M. Fafchamps
I. Venneman
J-M. Crielaard
A. Juchmès-Ferir
C. Lhermerout
M. Lamy
C. Deby
author_sort J-L. Croisier
collection DOAJ
description To test the hypothesis that delayed onset muscular soreness (DOMS) following intense eccentric muscle contraction could be due to increased production of prostaglandin E2 (PGE2), ten healthy male subjects were studied. Using a double-blind randomized crossover design, each subject performed two isokinetic tests separated by a period of at least 6 weeks: once with placebo, and once with piroxicam (Feldene®). They were given one capsule containing either placebo or piroxicam (20 mg) per day for 6 days with initial doses given starting 3 days prior to isokinetic testing. Exercise consisted of eight stages of five maximal contractions of the knee extensor and flexor muscle groups of both legs separated by 1 min rest phases, on a Kin Trex device at 60°/s angular velocity. The subjective presence and intensity of DOMS were evaluated using a visual analogue scale immediately after, and 24 and 48 h after each test. The mean plasma concentration of PGE2 measured at rest and after exercise was significantly lower in the group treated with piroxicam (p < 0.05). However, statistical analysis (two-way ANOVA test) revealed that exercise did not cause any significant change of mean plasma PGE2 over time in either of the two groups. Eccentric work was followed by severe muscle pain in extensor and flexor muscle groups. Maximal soreness was noted 48 h postexercise. Serum creatine kinase activity and the serum concentration of myoglobin increased significantly, and reached peak values 48 h after exercise in both experimental conditions (p < 0.001). By paired t-test, it appeared that there were no significant differences in the serum levels of these two markers of muscle damage between the two groups at any time point. We conclude that: (1) oral administration of piroxicam fails to reduce muscle damage and DOMS caused by strenuous eccentric exercise; and (2) the hypothetical role of increased PGE2 production in eccentric exercise-induced muscle damage, DOMS, and reduced isokinetic performance is not substantiated by the present results.
format Article
id doaj-art-b87f2e8c6f3e4d539398b7e20bcbc85b
institution DOAJ
issn 0962-9351
1466-1861
language English
publishDate 1996-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-b87f2e8c6f3e4d539398b7e20bcbc85b2025-08-20T03:22:49ZengWileyMediators of Inflammation0962-93511466-18611996-01-015323023410.1155/S0962935196000336Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exerciseJ-L. Croisier0G. Camus1T. Monfils2G. Deby-Dupon3M. Fafchamps4I. Venneman5J-M. Crielaard6A. Juchmès-Ferir7C. Lhermerout8M. Lamy9C. Deby10Department of Physical Medicine and Rehabilitation, Institute of Chemistry, BelgiumCenter for the Biochemistry of Oxygen, Institute of Chemistry, BelgiumDepartment of Physical Medicine and Rehabilitation, Institute of Chemistry, BelgiumCenter for the Biochemistry of Oxygen, Institute of Chemistry, BelgiumDepartment of Physical Medicine and Rehabilitation, Institute of Chemistry, BelgiumDepartment of Anesthesiology and Intensive Care Medicine, ISEPK, BelgiumDepartment of Physical Medicine and Rehabilitation, Institute of Chemistry, BelgiumDepartment of Clinical Biology, CHU, University of Liège, Sart Tilman, Liège B-4000, BelgiumLaboratory of Human Applied Physiology, ISEPK, BelgiumCenter for the Biochemistry of Oxygen, Institute of Chemistry, BelgiumCenter for the Biochemistry of Oxygen, Institute of Chemistry, BelgiumTo test the hypothesis that delayed onset muscular soreness (DOMS) following intense eccentric muscle contraction could be due to increased production of prostaglandin E2 (PGE2), ten healthy male subjects were studied. Using a double-blind randomized crossover design, each subject performed two isokinetic tests separated by a period of at least 6 weeks: once with placebo, and once with piroxicam (Feldene®). They were given one capsule containing either placebo or piroxicam (20 mg) per day for 6 days with initial doses given starting 3 days prior to isokinetic testing. Exercise consisted of eight stages of five maximal contractions of the knee extensor and flexor muscle groups of both legs separated by 1 min rest phases, on a Kin Trex device at 60°/s angular velocity. The subjective presence and intensity of DOMS were evaluated using a visual analogue scale immediately after, and 24 and 48 h after each test. The mean plasma concentration of PGE2 measured at rest and after exercise was significantly lower in the group treated with piroxicam (p < 0.05). However, statistical analysis (two-way ANOVA test) revealed that exercise did not cause any significant change of mean plasma PGE2 over time in either of the two groups. Eccentric work was followed by severe muscle pain in extensor and flexor muscle groups. Maximal soreness was noted 48 h postexercise. Serum creatine kinase activity and the serum concentration of myoglobin increased significantly, and reached peak values 48 h after exercise in both experimental conditions (p < 0.001). By paired t-test, it appeared that there were no significant differences in the serum levels of these two markers of muscle damage between the two groups at any time point. We conclude that: (1) oral administration of piroxicam fails to reduce muscle damage and DOMS caused by strenuous eccentric exercise; and (2) the hypothetical role of increased PGE2 production in eccentric exercise-induced muscle damage, DOMS, and reduced isokinetic performance is not substantiated by the present results.http://dx.doi.org/10.1155/S0962935196000336
spellingShingle J-L. Croisier
G. Camus
T. Monfils
G. Deby-Dupon
M. Fafchamps
I. Venneman
J-M. Crielaard
A. Juchmès-Ferir
C. Lhermerout
M. Lamy
C. Deby
Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise
Mediators of Inflammation
title Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise
title_full Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise
title_fullStr Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise
title_full_unstemmed Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise
title_short Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise
title_sort piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise
url http://dx.doi.org/10.1155/S0962935196000336
work_keys_str_mv AT jlcroisier piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise
AT gcamus piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise
AT tmonfils piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise
AT gdebydupon piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise
AT mfafchamps piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise
AT ivenneman piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise
AT jmcrielaard piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise
AT ajuchmesferir piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise
AT clhermerout piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise
AT mlamy piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise
AT cdeby piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise